Skip to main content
  • Jardiance May Help Heart by Shifting Its Fuel

    Animal study supports mechanism for glucose-independent effects

    The SGLT2 inhibitor empagliflozin (Jardiance) shifted myocardial metabolism from glucose to other more energy-efficient metabolites in a pig model, researchers said, suggesting a mechanism for its cardiac benefits beyond glucose lowering.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details